Keros Therapeutics, Inc.

NASDAQ:KROS

13.35 (USD) • At close June 30, 2025
Bedrijfsnaam Keros Therapeutics, Inc.
Symbool KROS
Munteenheid USD
Prijs 13.35
Beurswaarde 542,215,590
Dividendpercentage 0%
52-weken bereik 9.12 - 72.37
Industrie Biotechnology
Sector Healthcare
CEO Dr. Jasbir S. Seehra Ph.D.
Website https://www.kerostx.com

An error occurred while fetching data.

Over Keros Therapeutics, Inc.

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell

Vergelijkbare Aandelen

REGENXBIO Inc. logo

REGENXBIO Inc.

RGNX

8.21 USD

Syndax Pharmaceuticals, Inc. logo

Syndax Pharmaceuticals, Inc.

SNDX

9.365 USD

National Research Corporation logo

National Research Corporation

NRC

16.8 USD

Morphic Holding, Inc. logo

Morphic Holding, Inc.

MORF

56.99 USD

Mirum Pharmaceuticals, Inc. logo

Mirum Pharmaceuticals, Inc.

MIRM

50.89 USD

Sana Biotechnology, Inc. logo

Sana Biotechnology, Inc.

SANA

2.73 USD

Enanta Pharmaceuticals, Inc. logo

Enanta Pharmaceuticals, Inc.

ENTA

7.56 USD

Treace Medical Concepts, Inc. logo

Treace Medical Concepts, Inc.

TMCI

5.88 USD

Aclaris Therapeutics, Inc. logo

Aclaris Therapeutics, Inc.

ACRS

1.42 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)